Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized ...

In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...

Inebilizumab showed significant efficacy in improving MG-ADL and QMG scores in gMG patients compared to placebo over 26 weeks. The trial included 238 patients, with 80% AChR+ and 20% MuSK+ ...

Inebilizumab significantly reduced the risk of treated and AC-determined IgG4-RD flare by 87% compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- Amgen ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...